Skip to main content
. 2017 Jul 25;80(3):599–608. doi: 10.1007/s00280-017-3380-z

Fig. 2.

Fig. 2

a RAISE overall survival by ramucirumab Cmin,ss exposure quartile. Ramucirumab Cmin,ss quartile concentrations: Q1 (<25%) <49.7 µg/mL, Q2 (25% to <50%) 49.7 to <62.6 µg/mL, Q3 (50% to <75%) 62.6 to <81.1 µg/mL, Q4 (≥75%) ≥81.1 µg/mL. b RAISE progression-free survival by ramucirumab Cmin,ss exposure quartile. Ramucirumab Cmin,ss quartile sconcentrations: Q1 (<25%) <49.7 µg/mL, Q2 (25% to <50%) 49.7 to <62.6 µg/mL, Q3 (50% to <75%) 62.6 to <81.1 µg/mL, Q4 (≥75%) ≥81.1 µg/mL Cmin,ss, minimum concentration at steady state; PBO placebo; Q quartile; RAM ramucirumab